I'm a Pathologist. Ozempic & Mounjaro Aren't Actually Weight Loss Drugs (What GLP-1s Do Inside Your Body)

Ozempic and Mounjaro aren't actually weight loss drugs. I'm a pathologist, and in this episode I show you what GLP-1 medications do inside your body. I also cover the one thing that decides whether they change your life or quietly leave you worse off than where you started.

In 2005, the FDA approved a diabetes drug. Then something nobody planned for happened. Hearts got stronger. Kidneys healed. Sleep apnea reversed. Women with PMOS (formerly called PCOS) started ovulating again. For 20 years, nobody had a clean explanation for why one class of drugs did all of this. Now we do.

I'm Dr. Amin Hedayat, a triple board-certified physician and medical school assistant clinical professor. I break down what Ozempic, Mounjaro, Wegovy, Foundayo and Zepbound do at the cellular level, why the miracle crowd and the poison crowd both get it wrong, and the bridge framework that decides whether these drugs work for you or backfire.

In this episode:
Why GLP-1 was never only a blood sugar drug
The clue from the SELECT trial that broke the case open
3 silent habits that weaken your body's natural GLP-1 signal
The honest picture on muscle loss, cancer risk and side effects
5 foundations that decide whether your results last
What the FLOW kidney trial and the 2024 sleep apnea data show

Chapters
00:00 The Mystery
02:16 Where the Drug Came From
04:13 The Clue Everyone Missed
04:58 The Answer: A Master Signal
06:45 Why the Signal Goes Quiet
07:10 The Bridge
09:54 Two Myths
14:03 The Five Foundations
17:25 The Bigger Picture (One Fire, Many Rooms)
18:40 What the Evidence Actually Shows
20:46 Inner Circle and Close

Free GLP-1 resources and the Get Uninflamed Inner Circle: getuninflamed.com
Watch on YouTube: @draminhedayat
Instagram: @draminhedayat

References
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391(2):109-121.
Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205.
Zhou L, et al. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome. BMC Endocr Disord. 2023;23(1):245.
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084.
Sanyal AJ, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099.

Medical disclaimer: This episode is general medical education, not personal medical advice. Decisions about GLP-1 medications, dosing and treatment belong with your own physician. I'm an independent educator. I'm not directly or indirectly affiliated with any pharmaceutical company, and I have no financial disclosures.